Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus

Makoto Yamasaki, Hiroshi Miyata, Koji Tanaka, Osamu Shiraishi, Masaaki Motoori, Y. F. Peng, Takushi Yasuda, Masahiko Yano, Hitoshi Shiozaki, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Objective: Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative. To this end, we conducted a multicenter phase I/II trial of docetaxel, cisplatin, and fluorouracil (DCF) combination chemotherapy for ESCC. Methods: The study subjects were 46 patients with advanced or recurrent ESCC. Treatment included docetaxel at 60, 70, and 75 mg/m2, cisplatin at 70 mg/m2 on day 1, and daily fluorouracil at 700 mg/m2 on days 1 through 5. The recommended dose of docetaxel was determined in phase I, while the response rate (RR) and progression-free survival rates were analyzed in phase II. Results: The recommended dose was determined to be 70 mg/m2 in phase I. In phase II, the RR was 72.5%. Interim analysis showed median and 1-year progression-free survival of 14 months and 55.6%, respectively. Grade 3/4 toxicities of leukopenia and neutropenia occurred in 72.5 and 90% of patients, respectively. No treatment-related death was recorded. Surgical resection was subsequently performed in 20 patients after chemotherapy, and curative resection was achieved in 19. Conclusion: DCF was tolerable and effective for advanced and recurrent ESCC. Such findings might encourage a change in the treatment strategy for ESCC.

Original languageEnglish
Pages (from-to)307-313
Number of pages7
JournalOncology
Volume80
Issue number5-6
DOIs
Publication statusPublished - Aug 1 2011

Fingerprint

docetaxel
Combination Drug Therapy
Fluorouracil
Cisplatin
Esophagus
Squamous Cell Carcinoma
Disease-Free Survival
Therapeutics
Leukopenia
Neutropenia
Survival Rate
Esophageal Squamous Cell Carcinoma
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. / Yamasaki, Makoto; Miyata, Hiroshi; Tanaka, Koji; Shiraishi, Osamu; Motoori, Masaaki; Peng, Y. F.; Yasuda, Takushi; Yano, Masahiko; Shiozaki, Hitoshi; Mori, Masaki; Doki, Yuichiro.

In: Oncology, Vol. 80, No. 5-6, 01.08.2011, p. 307-313.

Research output: Contribution to journalArticle

Yamasaki, M, Miyata, H, Tanaka, K, Shiraishi, O, Motoori, M, Peng, YF, Yasuda, T, Yano, M, Shiozaki, H, Mori, M & Doki, Y 2011, 'Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus', Oncology, vol. 80, no. 5-6, pp. 307-313. https://doi.org/10.1159/000329806
Yamasaki, Makoto ; Miyata, Hiroshi ; Tanaka, Koji ; Shiraishi, Osamu ; Motoori, Masaaki ; Peng, Y. F. ; Yasuda, Takushi ; Yano, Masahiko ; Shiozaki, Hitoshi ; Mori, Masaki ; Doki, Yuichiro. / Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. In: Oncology. 2011 ; Vol. 80, No. 5-6. pp. 307-313.
@article{fe837295de544e279816b4cea7af65e9,
title = "Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus",
abstract = "Objective: Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative. To this end, we conducted a multicenter phase I/II trial of docetaxel, cisplatin, and fluorouracil (DCF) combination chemotherapy for ESCC. Methods: The study subjects were 46 patients with advanced or recurrent ESCC. Treatment included docetaxel at 60, 70, and 75 mg/m2, cisplatin at 70 mg/m2 on day 1, and daily fluorouracil at 700 mg/m2 on days 1 through 5. The recommended dose of docetaxel was determined in phase I, while the response rate (RR) and progression-free survival rates were analyzed in phase II. Results: The recommended dose was determined to be 70 mg/m2 in phase I. In phase II, the RR was 72.5{\%}. Interim analysis showed median and 1-year progression-free survival of 14 months and 55.6{\%}, respectively. Grade 3/4 toxicities of leukopenia and neutropenia occurred in 72.5 and 90{\%} of patients, respectively. No treatment-related death was recorded. Surgical resection was subsequently performed in 20 patients after chemotherapy, and curative resection was achieved in 19. Conclusion: DCF was tolerable and effective for advanced and recurrent ESCC. Such findings might encourage a change in the treatment strategy for ESCC.",
author = "Makoto Yamasaki and Hiroshi Miyata and Koji Tanaka and Osamu Shiraishi and Masaaki Motoori and Peng, {Y. F.} and Takushi Yasuda and Masahiko Yano and Hitoshi Shiozaki and Masaki Mori and Yuichiro Doki",
year = "2011",
month = "8",
day = "1",
doi = "10.1159/000329806",
language = "English",
volume = "80",
pages = "307--313",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "5-6",

}

TY - JOUR

T1 - Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus

AU - Yamasaki, Makoto

AU - Miyata, Hiroshi

AU - Tanaka, Koji

AU - Shiraishi, Osamu

AU - Motoori, Masaaki

AU - Peng, Y. F.

AU - Yasuda, Takushi

AU - Yano, Masahiko

AU - Shiozaki, Hitoshi

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Objective: Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative. To this end, we conducted a multicenter phase I/II trial of docetaxel, cisplatin, and fluorouracil (DCF) combination chemotherapy for ESCC. Methods: The study subjects were 46 patients with advanced or recurrent ESCC. Treatment included docetaxel at 60, 70, and 75 mg/m2, cisplatin at 70 mg/m2 on day 1, and daily fluorouracil at 700 mg/m2 on days 1 through 5. The recommended dose of docetaxel was determined in phase I, while the response rate (RR) and progression-free survival rates were analyzed in phase II. Results: The recommended dose was determined to be 70 mg/m2 in phase I. In phase II, the RR was 72.5%. Interim analysis showed median and 1-year progression-free survival of 14 months and 55.6%, respectively. Grade 3/4 toxicities of leukopenia and neutropenia occurred in 72.5 and 90% of patients, respectively. No treatment-related death was recorded. Surgical resection was subsequently performed in 20 patients after chemotherapy, and curative resection was achieved in 19. Conclusion: DCF was tolerable and effective for advanced and recurrent ESCC. Such findings might encourage a change in the treatment strategy for ESCC.

AB - Objective: Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative. To this end, we conducted a multicenter phase I/II trial of docetaxel, cisplatin, and fluorouracil (DCF) combination chemotherapy for ESCC. Methods: The study subjects were 46 patients with advanced or recurrent ESCC. Treatment included docetaxel at 60, 70, and 75 mg/m2, cisplatin at 70 mg/m2 on day 1, and daily fluorouracil at 700 mg/m2 on days 1 through 5. The recommended dose of docetaxel was determined in phase I, while the response rate (RR) and progression-free survival rates were analyzed in phase II. Results: The recommended dose was determined to be 70 mg/m2 in phase I. In phase II, the RR was 72.5%. Interim analysis showed median and 1-year progression-free survival of 14 months and 55.6%, respectively. Grade 3/4 toxicities of leukopenia and neutropenia occurred in 72.5 and 90% of patients, respectively. No treatment-related death was recorded. Surgical resection was subsequently performed in 20 patients after chemotherapy, and curative resection was achieved in 19. Conclusion: DCF was tolerable and effective for advanced and recurrent ESCC. Such findings might encourage a change in the treatment strategy for ESCC.

UR - http://www.scopus.com/inward/record.url?scp=79960549412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960549412&partnerID=8YFLogxK

U2 - 10.1159/000329806

DO - 10.1159/000329806

M3 - Article

C2 - 21778771

AN - SCOPUS:79960549412

VL - 80

SP - 307

EP - 313

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5-6

ER -